T1	Disease	14 36	ERCC1 -negative tumors
T2	Pharmacodynamic_phenotype	73 122	response to platinum -based chemotherapy compared
T3	Disease	140 168	ERCC1 -positive tumors , but
T4	Pharmacodynamic_phenotype	188 206	response rates did
T5	Phenotype	250 251	.
R1	increases	Arg1:T1	Arg2:T2
R2	treats	Arg1:T2	Arg2:T1
R3	influences	Arg1:T3	Arg2:T2
R4	influences	Arg1:T3	Arg2:T4
R5	influences	Arg1:T3	Arg2:T5
R6	increases	Arg1:T4	Arg2:T2
R7	influences	Arg1:T4	Arg2:T3
R8	influences	Arg1:T4	Arg2:T5
R9	isAssociatedWith	Arg1:T5	Arg2:T1
R10	isAssociatedWith	Arg1:T5	Arg2:T2
R11	isAssociatedWith	Arg1:T5	Arg2:T3
R12	isAssociatedWith	Arg1:T5	Arg2:T4
